NEW YORK, NY / ACCESSWIRE / November 17, 2017 / U.S. markets rallied back from the recent two day slump on Thursday on the strength of corporate earnings from Cisco and Wal-Mart. The Dow Jones Industrial Average gained 0.80 percent to close at 23,458.36, while the S&P 500 Index rose 0.82 percent to close at 2,585.64. The Nasdaq Composite Index spiked 1.30 percent to close at 6,793.29.

"Traders are trying to figure out whether today's positive move is just a bounce back or the beginning of the next upward move. US equities have enjoyed a very bullish run lately, so a pullback would not be a surprise," said David Madden, market analyst at CMC Markets, in a note, according to MarketWatch.

RDI Initiates Coverage on:

Spectrum Pharmaceuticals, Inc.
https://rdinvesting.com/news/?ticker=SPPI

Myriad Genetics, Inc.
https://rdinvesting.com/news/?ticker=MYGN

Spectrum Pharmaceuticals, Inc.'s stock jumped 5.44% Thursday, to close the day at $20.73. The stock recorded a trading volume of 1,536,868 shares, which was below its three months average volume of 1,800,190 shares. In the last year Spectrum Pharmaceuticals, Inc.'s shares have traded in a range of 3.85 - 21.95. The share price has gained 438.44% from its 52-week low. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $16.98 is greater than its 200-day moving average of $10.19. Shares of Spectrum Pharmaceuticals have gained roughly 48.71 percent in the past month and are up 367.95 percent year-to-date.

Access RDI's Spectrum Pharmaceuticals, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=SPPI

On Thursday, shares in Myriad Genetics, Inc. recorded a trading volume of 1,567,961 shares, which was above the three months average volume of 991,976 shares. The stock ended the day 6.91% higher at 33.41. The share price has gained 120.53% from its 52-week low with a 52-week trading range of 15.15 - 37.30.The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $34.17 is greater than its 200-day moving average of $27.92. Shares of Myriad Genetics, Inc. are trading at a Price to Earnings ratio of 104.73. Shares of Myriad Genetics have fallen roughly 7.45 percent in the past month and are up 100.42 percent year-to-date.

Access RDI's Myriad Genetics, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=MYGN

Our Actionable Research on Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) and Myriad Genetics, Inc. (NASDAQ:MYGN) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com